Asia On The Move: Personnel News From AstraZeneca, Novartis, Teva
This article was originally published in The Pink Sheet Daily
AstraZeneca Japan appoints a 38-year old president, Novartis Japan selects a woman CEO and Teva recruits a Lilly veteran to head its operation in Japan. These moves and others are profiled in this edition of Asia On The Move.
You may also be interested in...
Touting its coronavirus vaccines as a "global public good", China is quietly preparing for the first general approvals and launches, possibly within weeks, developers say. But who will be first in line to receive them? And at what cost? Distribution and pricing are just some of the unanswered questions.
China is set to grant priority reviews to major biologics from Roche, the first CAR-T therapy from Wuxi Juno, and breakthrough therapy designation to a pediatric respiratory antiviral from ArkBio.
China’s National Medical Products Administration has released key regulations and proposals designed to encourage first generics through a 12-month market exclusivity proposal.